Nano Carrier IR report 2017

3/12

NC-6004 RestartedNew clinical development programs also starting　In the clinical trials, by exploring various pos-sibilities, NanoCarrier is implementing a devel-opment strategy that expands the number of regions and indications in order to increase the probability of success to get approval of clinical candidates and expand the market quickly. 　Among these, we decided in April 2017 to restart the Phase III clinical studies of NC-6004 for the indication of pancreatic cancer that had been temporarily suspended. At present, we are investing the possibility of combination therapy not only with gemcitabine but also with 5-FU+cetuximab.　We have also commenced Phase I clinical studies of NC-6300 in the U.S. for indications of rare cancers. We are moving forward with projects aiming at obtaining early approval. We are conducting non-clinical studies of NC-6201 aiming at its development as an improved medicine that should be a high-qual-ity active-type model.Aiming at securing a new business and technology basis through fusion with superior technology　We are continuing joint development of a nucleic acid delivery technology together with Chugai Pharmaceutical. The utility value of our technology is steadily rising as the number of nucleic acid drugs has been recently gradually increasing. Furthermore, we also continue to take up new challenges in the cosmetics busi-ness being jointly conducted with Albion Co., Ltd., such as the new product launches planned for this scal year.　Moreover, deliberations continue to move forward concerning partnerships with high-po-tential companies and businesses. Through these kinds of cooperation, we are now begin-ning to see a new facet of the future of our company. We are proceeding pro-actively to establish a new technological platform through the combination of technologies, such as the conclusion of an investment and joint research agreement with TPG Biologics, Inc. (Taiwan) in March 2017, and the conclusion of an agreement with the University of Utah (U.S.) Pharmaceutical Chemistry Group for joint research on oral protein preparations in April 2017.3Directions for the scal year ending March 31, 2018In: Millions of yen(123)2,1292,252(71)(2,747)(2,676)Net loss13(2,606)(2,619)Ordinaryloss28(2,684)(2,712)Gross operatingloss492,8812,930Selling, generaland administrativeexpensesResearchand developmentexpenses(21)197218Net salesDierenceFiscal year ending March 31, 2018 (projection)Fiscal year endedMarch 31, 2017 (actual)The scal year ending March 2018 will be a "turning point" that is designed to take us to the next stage. We will strive towards our goals with a new organizational structure.Meaningful clinical development aimed at obtaining early approvalGeneration of new pipelinesApproaches to new technologyBusiness development activities such as joint development and licensingProgress in the cosmetics business